COR · Consumer

Cencora, Inc.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-06

• Acquisition / Partnership / DivestitureImportance 59 · Surprise 60
  Cencora proposed a $3.5 billion acquisition involving Covetrus and announced plans to sell MWI Animal Health to Covetrus. The transaction would combine two major veterinary-product suppliers and includes veterinary…
• Capital Return ProgramImportance 40 · Surprise 42
  Cencora repurchased $1 billion of its shares during the period covered by the fiscal third-quarter reporting. The company also continues to return capital through dividends. The buybacks accompanied the increase in…
• Operating Margin DriversImportance 30 · Surprise 40
  Adjusted operating income increased 17% year over year in fiscal third quarter 2026. Adjusted gross profit rose 23%, supported by the OneOncology acquisition and a richer specialty-product mix. Strong specialty growth…

10-Q · 2026-08-05

• Outstanding IndebtednessImportance 89 · Surprise 82
  Total debt was $11.7 billion as of June 30, 2026, consisting of $10.1 billion of fixed-rate debt and $1.6 billion of variable-rate debt. Cencora issued $3.0 billion of senior notes and borrowed $1.5 billion of…
• Acquisitions and DivestituresImportance 65 · Surprise 60
  Cencora completed its acquisition of OneOncology in February 2026, using $4.6 billion of cash in investing activities and financing part of the transaction with $3.0 billion of senior notes and $1.5 billion of…
• Interest Rate ExposureImportance 65 · Surprise 82
  Net interest expense increased 65.4% year over year to $353.6 million in the nine months ended June 30, 2026, primarily because of debt issued to finance the OneOncology acquisition and the May 2025 issuance of €1.0…
• Gross Margin DriversImportance 61 · Surprise 66
  Gross profit increased 24.1% year over year to $3.6 billion in the June 2026 quarter and 20.4% to $10.3 billion for the nine-month period. U.S. Healthcare Solutions gross profit rose 31.2% to $2.4 billion in the…
• Opioid Litigation LiabilityImportance 58 · Surprise 42
  As of June 30, 2026, Cencora had $4.2 billion of accrued liabilities for the Distributor Settlement Agreement and other opioid-related litigation settlements. The liability is expected to be paid over the next 13…
• Operating Cash Flow TrendsImportance 51 · Surprise 64
  Operating cash flow increased by $1.0 billion to $1.7 billion in the nine months ended June 30, 2026 from $0.7 billion in the comparable 2025 period. The 2026 cash flow included $3.0 billion of net income and a $0.6…
• Operating Expense TrendsImportance 47 · Surprise 48
  Total operating expenses increased 21.9% year over year to $2.5 billion in the June 2026 quarter and 22.5% to $7.2 billion for the nine-month period. Distribution, selling, and administrative expense increased 27.5% to…
• Capital ExpendituresImportance 47 · Surprise 48
  Capital expenditures increased to $511.0 million in the nine months ended June 30, 2026 from $418.2 million in the prior-year period. The spending supported continued expansion and enhancement of the distribution…
• GLP-1 Product DemandImportance 47 · Surprise 48
  Sales of products labeled for diabetes and/or weight loss in the GLP-1 class increased $2.3 billion, or 25.5%, in the quarter and $5.2 billion, or 19.7%, year to date. GLP-1 demand was a major contributor to U.S.…
• Capital Return ProgramImportance 46 · Surprise 42
  Cencora repurchased $1.0 billion of common stock in the nine months ended June 30, 2026. The company used $882.2 million to complete its prior $2.0 billion authorization and repurchased another $117.8 million under a…
• Digital Transformation InvestmentImportance 46 · Surprise 42
  Cencora has committed $652 million to support the primary enterprise resource planning system upgrade for its U.S. Healthcare Solutions segment. The company also has $558 million of commitments for other digital…
• Revenue Performance and MixImportance 43 · Surprise 32
  Revenue increased 5.1% year over year to $84.8 billion in the June 2026 quarter and 4.8% to $249.0 billion for the nine-month period. U.S. Healthcare Solutions revenue rose 4.9% to $74.9 billion in the quarter and 4.3%…
• Geographic Market CommentaryImportance 43 · Surprise 32
  International Healthcare Solutions revenue increased 5.9% in the quarter and 9.4% year to date, led by the European distribution business. Other Healthcare Solutions revenue increased 10.8% year to date, while the…
• Liquidity and Debt PositionImportance 38 · Surprise 24
  Cencora had $1.6 billion of variable-rate debt outstanding as of June 30, 2026, exposing interest expense to fluctuations in short-term rates. The company held $2.8 billion in cash and cash equivalents on the same…
• Market Demand TrendsImportance 37 · Surprise 32
  U.S. Healthcare Solutions revenue increased 4.9% in the quarter and 4.3% year to date, primarily because of overall market growth and higher unit volumes. Demand was strongest for specialty products sold to health…
• FX / Currency HeadwindsImportance 37 · Surprise 6
  Cencora has foreign-exchange exposure primarily to the U.K. pound sterling, euro, Turkish lira, Brazilian real, and Canadian dollar through its non-U.S. operations. Foreign operations represented approximately 10% of…
• Headcount / RestructuringImportance 34 · Surprise 42
  Restructuring and other expenses totaled $60.6 million in the June 2026 quarter and $115.7 million for the nine-month period. Restructuring and employee severance costs were $38.9 million in the quarter and $70.4…
• Supply Chain and InventoryImportance 31 · Surprise 32
  Inventory increased by $1.0 billion during the nine months to support higher business volume, while accounts payable increased by $0.6 billion because of the larger inventory balance and supplier-payment timing. Days…
• Distribution Network ExpansionImportance 26 · Surprise 24
  Cencora continued expanding and enhancing its distribution network during the nine months ended June 30, 2026. Distribution-network investments were among the company’s significant capital expenditures, alongside…
• Türkiye Inflationary ImpactImportance 25 · Surprise 32
  Cencora accounts for Türkiye as a highly inflationary economy, and the continued weakening of the Turkish lira generated cost of goods sold expense of $38.4 million in the nine months ended June 30, 2026, up 5.6% from…
• Income Tax Rate ChangesImportance 18 · Surprise 14
  The effective tax rate declined to 22.1% in the June 2026 quarter from 23.0% in the prior-year quarter. The nine-month effective tax rate declined to 21.6% from 22.3% year over year. U.S. state income taxes increased…
• Customer DynamicsImportance 17 · Surprise 24
  The company reported lost sales from an oncology customer and a grocery customer during the nine-month period, as well as lower sales to a large mail-order customer following brand conversions. Customer consolidation…

8-K · 2026-08-05

• Liquidity and Debt PositionImportance 89 · Surprise 82
  Cash and cash equivalents declined to $2.815 billion at June 30, 2026, from $4.356 billion at September 30, 2025. Long-term debt increased to $11.444 billion from $7.543 billion, and short-term debt increased to $279.2…
• Guidance and OutlookImportance 73 · Surprise 76
  Cencora raised fiscal 2026 adjusted diluted EPS guidance from $17.70-$17.90 to $17.75-$17.95. The company expects consolidated revenue growth of 4%-6%, adjusted operating income growth of 13%-14%, and adjusted free…
• Acquisition / Partnership / DivestitureImportance 65 · Surprise 60
  Cencora’s February 2026 acquisition of OneOncology materially affected its operating structure and financial outlook. The company reported $4.97 billion of cash spent on acquired companies during the nine months ended…
• Capital Return ProgramImportance 65 · Surprise 82
  Cencora repurchased $1.0 billion of common stock during the third fiscal quarter, completing the amount previously expected by the end of calendar 2026. Nine-month purchases of common stock totaled $1.000 billion…
• Gross Margin DriversImportance 61 · Surprise 66
  GAAP gross profit increased 24.1% year over year to $3.6 billion in the third quarter, while gross margin expanded 66 basis points to 4.26%. The margin expansion was primarily driven by higher U.S. Healthcare Solutions…
• Operating Expense TrendsImportance 55 · Surprise 66
  GAAP operating expenses increased 21.9% year over year to $2.5 billion, or 2.93% of revenue, in the third quarter. Distribution, selling, and administrative expense increased 27.5% to $2.13 billion, while acquisition…
• Operating Cash Flow and Capital ExpendituresImportance 51 · Surprise 64
  Nine-month operating cash flow increased to $1.688 billion from $741.7 million in the prior-year period. Capital expenditures increased to $511.0 million from $418.2 million, while cash used for acquisitions totaled…
• Revenue Performance and MixImportance 49 · Surprise 32
  Third-quarter revenue increased 5.1% year over year to $84.8 billion for the quarter ended June 30, 2026. U.S. Healthcare Solutions revenue rose 4.9% to $74.9 billion, driven by unit-volume growth in specialty products…
• Market Demand TrendsImportance 49 · Surprise 32
  U.S. Healthcare Solutions revenue increased 4.9% to $74.9 billion, primarily reflecting overall market growth driven by unit volume. Demand was strongest for specialty products sold to health systems and physician…
• Litigation and Legal RiskImportance 47 · Surprise 60
  Cencora recorded a $102.0 million reduction in opioid liability in the third quarter after opioid litigation was dismissed. For the nine months ended June 30, 2026, the company also recorded an $86.8 million credit…
• Geographic Market CommentaryImportance 43 · Surprise 48
  International Healthcare Solutions revenue increased 5.9% to $7.7 billion in the quarter, or 6.1% on a constant-currency basis. Growth was primarily generated by the European distribution business and global specialty…
• Operating Income and MarginsImportance 41 · Surprise 48
  GAAP operating income increased 29.1% year over year to $1.1 billion, and GAAP operating margin expanded 24 basis points to 1.32%. Adjusted operating income increased 17.0% to $1.2 billion, with adjusted operating…
• Income Tax Rate ChangesImportance 25 · Surprise 32
  The GAAP effective tax rate declined to 22.1% in the third quarter from 23.0% in the prior-year quarter. The adjusted effective tax rate declined to 19.9% from 20.7%. Third-quarter GAAP income tax expense was $219.7…
• Products and TechnologyImportance 23 · Surprise 24
  Product mix included increased sales of specialty pharmaceuticals to health systems and physician practices and higher sales of GLP-1 products used for diabetes and/or weight loss. GLP-1 products carry lower gross…
• Customer DynamicsImportance 17 · Surprise 24
  Cencora continued to experience customer-related offsets in its U.S. Healthcare Solutions business. The company identified the 2025 loss of an oncology customer as a drag on revenue and segment operating income. Sales…

News · 2026-08-05

• Guidance / OutlookImportance 51 · Surprise 60
  Cencora raised its fiscal 2026 adjusted earnings forecast after reporting third-quarter results on August 5, 2026. Reuters attributed the increase to strong demand for specialty medicines. Other coverage reported…
• Capital Return ProgramImportance 40 · Surprise 42
  Cencora repurchased $1 billion of its shares during the period covered by the fiscal third-quarter reporting. The company also continues to return capital through dividends. The buybacks accompanied the increase in…
• Liquidity and Debt PositionImportance 40 · Surprise 42
  Cencora expanded its multi-currency revolving credit facility to $7 billion and extended its maturity to 2031. The company amended its receivables securitization facility by reducing its base size while doubling its…
• Revenue Performance and MixImportance 36 · Surprise 14
  Cencora’s fiscal third-quarter revenue increased 5.1% year over year to $84.8 billion for the quarter ended June 30, 2026. Growth was driven by higher volume in both the U.S. Healthcare Solutions and International…
• Operating Margin DriversImportance 30 · Surprise 40
  Adjusted operating income increased 17% year over year in fiscal third quarter 2026. Adjusted gross profit rose 23%, supported by the OneOncology acquisition and a richer specialty-product mix. Strong specialty growth…
• Market Demand TrendsImportance 20 · Surprise 24
  Cencora reported strong demand for specialty medicines in the quarter, supporting growth in its pharmaceutical distribution business. Specialty products and GLP-1 diabetes and weight-loss medicines were identified as…
• Competition and Market ShareImportance 10 · Surprise 6
  Cencora, McKesson and Cardinal Health together account for more than 90% of the U.S. drug distribution market, indicating a highly concentrated competitive structure. Cencora is one of three leading domestic…

News · 2026-08-04

• Acquisition / Partnership / DivestitureImportance 59 · Surprise 60
  Cencora proposed a $3.5 billion acquisition involving Covetrus and announced plans to sell MWI Animal Health to Covetrus. The transaction would combine two major veterinary-product suppliers and includes veterinary…
• Regulatory RiskImportance 51 · Surprise 60
  The U.S. Federal Trade Commission is scrutinizing Cencora’s proposed $3.5 billion acquisition of Covetrus. The FTC has sent information demands to customers and competitors to evaluate potential effects on…
• Capital Return ProgramImportance 40 · Surprise 42
  Cencora repurchased $1 billion of its shares during the period covered by the fiscal third-quarter reporting. The company also continues to return capital through dividends. The buybacks accompanied the increase in…